Amicus Therapeutics Inc. priced a $225 million debt offering.

The company will issue unsecured convertible notes due 2023 in a private placement with an option to purchase an additional $25 million worth of the debt.

The notes will bear interest at 3% per annum, with payments due semiannually starting June 15, 2017. They are convertible into company shares at an initial rate of $6.12 per share.

The issue is expected to close Dec. 21 and will help the company refinance a part of its existing debt.

Goldman Sachs & Co., J.P. Morgan Securities LLC, BofA Merrill Lynch and LEERINK Partners are acting as book runners for the offering. Cowen and Co. is acting as lead manager.